On May 2, 2022 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, reported that it will report its financial results for the first quarter ended March 31, 2022 and provide recent clinical and corporate updates via a press release on Thursday, May 5, 2022 at 4:05pm Eastern Time (ET) (Press release, Gritstone Oncology, MAY 2, 2022, View Source [SID1234613303]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To facilitate engagement with the company’s shareholder base and connections with its investors, Gritstone is partnering with Say Technologies to enable shareholders to submit and upvote questions through Say’s online portal, a selection of which will be answered by Gritstone management via a post on the IR section of the company’s website at View Source

From 9:00am ET Tuesday, May 3 through 5:00pm ET Friday, May 6, all shareholders can submit questions at the following link: View Source

Gritstone will then post a response addressing select questions after market close on Wednesday, May 11.

Shareholders can email [email protected] for any support inquiries.